DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Finafloxacin
Finafloxacin
The Role of Nanobiosensors in Therapeutic Drug Monitoring
Activity of the Investigational Fluoroquinolone Finafloxacin and Seven Other PD Dr
Paper I and II)
Against Helicobacter Pylori in Vitro and in Vivo Merlion Pharmaceuticals Pte Ltd, Washington DC 2008 05-01 the Capricorn, 1 2 1 1 3 3 1 Science Park 2, A
200 and 800 Mg) in Healthy Volunteers Receiving a Single Oral Dose
The Grohe Method and Quinolone Antibiotics
206307Orig1s000
Finafloxacin
Visão De Futuro Para Produção De Antibióticos: Tendências De Pesquisa, Desenvolvimento E Inovação
An in Situ High-Throughput Screen Identifies Inhibitors of Intracellular Burkholderia Pseudomallei with Therapeutic Efficacy
Stembook 2018.Pdf
A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
Antibiotics and Urinary Tract Infections
Influence of Ph on the Activity of Finafloxacin Against Extracellular
A Mini Review on the Study of New Broad-Spectrum Antimicrobial Fluoroquinolone JNJ-Q2
P1669 Poster Session VI New Quinolones, Oxazolidones, and A
(12) Patent Application Publication (10) Pub. No.: US 2011/0003803 A1 Stroman Et Al
6-Veterinary-Medicinal-Products-Criteria-Designation-Antimicrobials-Be-Reserved-Treatment
Top View
Quinolone Antibiotics
Selection and Characterisation of Finafloxacin, Ciprofloxacin And
Antibiotics Currently in Clinical Development
Finafloxacin
Activity of Finafloxacin, a Novel Fluoroquinolone with Increased
2019 Antibacterial Agents in Clinical Development
Pharmaabkommen A1 E
In Vivo Efficacy of Finafloxacin in Difficult
Bacterial Targets of Antibiotics in Methicillin-Resistant Staphylococcus Aureus
Antibiotics in the Clinical Pipeline in 2011
Looking for the New Preparations For
New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives
Novel Antibiotic Treatment for Skin and Soft Tissue Infection
S. Aureus (MRSA) (100) at Ph 7.2 and Ph 5.8 Figure 1
206307Orig1s000
Finafloxacin
XTORO (Finafloxacin Otic Suspension) 0.3% Nonsusceptible Organisms
Abx CE HO [Repaired]
Merlion and Dstl Awarded DTRA Grant to Explore the Use of Finafloxacin Against Biological Threat Agents
Novel Treatment Options for Multi-Drug Resistant Gram-Negative Infections
206307Orig1s000
The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
N206307 Finafloxacin Clinical BPCA
WHO Drug Information Vol
Fluoroquinolones for the Treatment of Urinary Tract Infection: a Review of Clinical Effectiveness, Cost- Effectiveness, and Guidelines
1 Class Update with New Drug Evaluation: Ototopical Antibiotics
Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated Or Fastidious Bacteria
Quinolones a Systematic Quest
ANTIBACTERIAL AGENTS in CLINICAL DEVELOPMENT an Analysis of the Antibacterial Clinical Development Pipeline, Including Tuberculosis
Fluoroquinolones: Are They All the Same (Or Not) ?
Medchemcomm Accepted Manuscript
2018 Update of Antibacterial Agents in Clinical Development Is Based on the Outcome of the Second Advisory Group Meeting That Was Held on 12 July 2018
Otic Antibiotics and Antibiotic-Steroid Combinations
A Dual-Mechanism Antibiotic Targets Gram-Negative Bacteria and Avoids Drug Resistance 11 1 1,5 1 1 12 James K
[Product Monograph Template